# MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)

> **NCT07479485** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Lepu Biopharma Co., Ltd.** · enrollment: 160 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** MRG006A
- **DRUG:** MRG006A
- **DRUG:** MRG006A

## Key facts

- **NCT ID:** NCT07479485
- **Lead sponsor:** Lepu Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2028-04
- **Final completion:** 2029-04
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07479485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07479485, "MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07479485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*